Use of a gentamicin‐citrate lock leads to lower catheter‐related bloodstream infection rates and reduced cost of care in hemodialysis patients. Issue 1 (1st October 2020)

• Record Type: Journal Article
• Authors: Hussein, Wael F.; Gomez, Norma; Sun, Sumi J.; Yu, Junhua; Yang, Fang; Ajuria, Michael; Abra, Graham E.; Schiller, Brigitte
• Is Part Of: Hemodialysis international. Volume 25:Issue 1(2021)
• Page Start: 20
• Page End: 28
• Publication Date: 2020-10-01
• Subjects: Central venous catheter -- hemodialysis -- catheter‐related bloodstream infections -- bacteremia -- hospitalization -- catheter lock solutions; Hemodialysis -- Periodicals; Renal Dialysis -- Periodicals; Renal Dialysis -- Congresses; Hemodialysis, Home -- Congresses; 617.461059
• DOI: 10.1111/hdi.12880
• Languages: English
• ISSNs: 1492-7535

Abstract

Abstract: Introduction: Central venous catheters (CVC) are a major contributor to infections in hemodialysis (HD) patients, leading to high morbidity and mortality. Gentamicin‐citrate (GC) lock is used as standard of care at centers belonging to a mid‐size dialysis organization. Four outpatient HD centers acquired by the organization continued to use heparin for catheter locks for a period of time before converting to the provider's standard of using GC lock. Methods: In this retrospective observational study, we included patients receiving HD by CVC at these four centers. We report rates of CVC‐related bloodstream infections (CVC‐BSI) during the heparin lock and the GC lock periods; crude rate ratios and adjusted rate ratios using Cox survival analyses adjusting for potential confounders; microbiology patterns; safety signals (gentamicin resistance, hospitalizations and deaths); and financial impact on payer. Findings: A total of 220 and 281 patients used tunneled CVCs, accounting for 25, 245 and 44, 550 catheter days in the heparin and the GC lock periods, respectively. CVC‐BSI event rates were 66% lower in the GC lock period (CVC‐BSI event rate: 0.20 per 1000 catheter‐days) than the heparin lock period (rate: 0.59 per 1000 catheter days); rate ratio 0.34 (95% confidence interval (CI) 0.15–0.78, P = 0.01). In the fully adjusted multivariable Cox model, use of GC lock was associated with 70% reduction in CVC‐BSI events (HR 0.30, 95% CI 0.12–0.72, P = 0.01). No increased risk of gentamicin resistance, hospitalizations, or death associated with use of GC lock were observed. Use of GC lock was associated with an estimated saving of $1533 (95% CI: $259–$4882) per patient per year. Discussion: Use of GC lock led to significant reductions in CVC‐BSIs with no signal for harm, and is associated with significant cost savings in dialysis care.